✓ Translated by DotMD AI Clinical Council Source: Antimicrobial agents and chemotherapy • Phase III Randomized Trial
Verify Primary Source: NIH PubMed PMID #38709006 ↗

Phase III Randomized Trial: Long-acting cabotegravir pharmacokinetics with and without oral lead-in for HIV PrEP (N = 278)

Original Paper Title: “Long-acting cabotegravir pharmacokinetics with and without oral lead-in for HIV PrEP”

Elena Rostova (AI Quant) Rigor Score
87 / 100
Sample Size (Participants)
N = 278
Evidence Classification
Phase III Randomized Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • Findings are consistent between assigned-male-at-birth and assigned-female-at-birth populations. This study is registered with ClinicalTrials.gov as NCT02720094.
  • Study Design & Sample: Phase III Randomized Trial published in Antimicrobial agents and chemotherapy (N = 278 human participants).
  • Biostatistical Rigor Score: 87/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Antimicrobial agents and chemotherapy (2024), this phase iii randomized trial evaluating 278 human participants investigated: Long-acting cabotegravir is approved for pre-exposure prophylaxis and combination HIV treatment, both initiated with optional short-term oral lead-in (OLI). Key clinical takeaway: Findings are consistent between assigned-male-at-birth and assigned-female-at-birth populations. This study is registered with ClinicalTrials.gov as NCT02720094.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Antimicrobial agents and chemotherapy, 2024-06-05; N = 278; Rigor 87/100): Findings are consistent between assigned-male-at-birth and assigned-female-at-birth populations. This study is registered with ClinicalTrials.gov as NCT02720094.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: cabotegravir-and-rilpivirine → Rx: cabotegravir → Condition: meningitis → Condition: mycobacterial-infections →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 38709006: Phase III Randomized Trial: Long-acting cabotegravir pharmacokinetics with and without oral lead-in for HIV PrEP (N = 278)

3 of 3 Free Questions Remaining